Envista, Dentsply Sirona, and Henry Schein, Inc. Release Financial Updates; Jilin Issues Oral Price Project Guidelines; Medit Acquires Orthodontic Continuing Education Institution and Establ…

Jilin Releases Dental Service Pricing Guidelines, Full Mouth Cleaning Total Cost Approximately 532 Yuan

On April 29, 2026, the Jilin Provincial Medical Security Bureau released the "Jilin Province Dental Medical Service Pricing Project Guidelines," clarifying pricing standards for provincial, ministerial, and municipal medical institutions. According to the guidelines, the total cost for full mouth cleaning (including polishing and sandblasting) based on 28 teeth is approximately 532 yuan. The fee for temporary fixed restoration is set at 136 yuan per tooth site, fixed restoration at 1,815 yuan per tooth site, full denture restoration at 4,000 yuan per single arch, complex tooth extraction at 250 yuan per tooth, and fully impacted complex wisdom tooth extraction at approximately 560 yuan per tooth. By the end of December 2026, all provinces nationwide must implement 114 dental medical service pricing project guidelines. Currently, 17 provinces, including Jilin, have completed their releases.

Dongguan Stomatological Hospital Renaming Dispute: Health Bureau Demands Rectification, Hospital Refuses to Comply and Seeks Legal Recourse

Recently, the Dongguan Municipal Health Bureau issued a rectification notice to the private Dongguan Stomatological Hospital, determining that its name violates Article 47 of the "Implementation Rules for the Regulations on the Administration of Medical Institutions," requiring it to submit a name change application by April 27. The hospital subsequently responded in writing, refusing to comply, and has entrusted a legal team to seek recourse in accordance with the law. A health work meeting on March 5, 2026, had proposed plans to jointly establish a public Dongguan Stomatological Hospital. As of now, the Health Bureau has not issued an official response to the hospital's refusal letter.

Medit Acquires Orthodontic Continuing Education Institution, Establishes Global Orthodontics Business Unit

On May 7, 2026, Medit completed the acquisition of Progressive Orthodontics (PO), an orthodontic continuing education institution, through its U.S. subsidiary, and established a global orthodontics business unit in Newport Beach, California. PO, founded over 40 years ago, has trained tens of thousands of practitioners in more than 60 countries. Its SmileStream program will gradually integrate with Medit's digital solutions. Medit's Aligners have been launched in the U.S. market and are planned for global expansion. Medit stated that this move will extend its dental ecosystem from pure scanning hardware to an integrated clinical workflow, strengthening its competitiveness in the rapidly evolving global orthodontics market.

Envista 2026 Q1: Sales of $705.6 Million, Core Revenue Up 9.5% Year-over-Year

On May 6, 2026, Envista Holdings Corporation announced its first-quarter 2026 results, with quarterly sales of $705.5 million, up 14.4% year-over-year, and core sales growth of 9.5% excluding currency and M&A impacts. Adjusted diluted earnings per share were $0.36, up 50% year-over-year, and the adjusted EBITDA margin rose to 14.0%. The board simultaneously authorized a new $300 million share repurchase program, valid until December 31, 2029.

Dentsply Sirona 2026 Q1: Net Sales in Asia Pacific of $115 Million, Up 6.3% Year-over-Year

On May 5, 2026, Dentsply Sirona reported its first-quarter 2026 financial results, with net sales of $880 million, up 0.1% year-over-year. However, the net loss attributable to shareholders was $10 million, compared to a profit of $20 million in the same period last year. Adjusted EBITDA for the quarter was $129 million, down 22.8% year-over-year, with the adjusted EBITDA margin falling to 14.7%. Orthodontics and Implant Solutions revenue was $199 million, down 8.1% year-over-year, while Connected Technology Solutions revenue grew 4.4% to $246 million. Revenue in the Americas fell 9.4% year-over-year, while EMEA grew 6.9% and Asia Pacific grew 6.3%. The company expects full-year 2026 net sales to be between $3.5 billion and $3.6 billion.

Henry Schein 2026 Q1: Global Dental Distribution Revenue of $1.766 Billion, Up 9.0% Year-over-Year

On May 5, 2026, Henry Schein, Inc. released its first-quarter 2026 financial report. Global dental distribution revenue was $1.766 billion, up 9.0% year-over-year, comprising dental consumables of $1.292 billion, dental equipment of $417 million, and value-added services of $57 million. During the quarter, the company acquired a U.S. S.I.N. dental implant distributor, generating a $11 million remeasurement gain, and spent $125 million to repurchase approximately 1.6 million shares of common stock. The value creation plan is expected to generate cumulative revenue growth of over $200 million in the coming years, with an annualized growth rate of $125 million by the end of 2026.

Solventum 2026 Q1: Dental Business Revenue of $354 Million, Up 7.9% Year-over-Year

On May 5, 2026, Solventum released its first-quarter 2026 earnings report. During the reporting period, the company achieved net sales of $2.007 billion, down 3.0% year-over-year, but up 2.1% on an organic basis. Dental business net sales were $354 million, up 7.9% year-over-year, with an organic growth rate of 3.4%. The company stated that dental business growth was driven by brand strength, product launches, and sales channel specialization. Despite cash flow pressure, Solventum maintained its full-year 2026 guidance, expecting organic sales growth of 2.0% to 3.0% and adjusted diluted earnings per share in the range of $6.40 to $6.60.

Zhonghong Oral 2026 Q1: Revenue of 19.4767 Million Yuan, Up 72.81%; Net Profit Attributable to Parent Up 43.02%

On May 7, 2026, Beijing Zhonghong Oral released its unaudited first-quarter 2026 financial statements. Operating revenue was 19.4767 million yuan, up 72.81% year-over-year; net profit attributable to the parent company was 1.5277 million yuan, up 43.02%; and net cash flow from operating activities was 4.1501 million yuan, turning positive. The company's cash balance was 29.943 million yuan.

WHOLE SHINE MEDICAL Receives Qualified Audit Opinion, Subsidiary's 51% Stake in Delun Medical Frozen

On April 28, 2026, WHOLE SHINE MEDICAL TECHNOLOGY CO., LTD. issued a special explanation for its 2025 annual report. The audit firm issued a qualified opinion on its financial statements, primarily due to a 6.68% equity investment in Fushun Bank, for which the auditor could not obtain sufficient audit evidence. WHOLE SHINE MEDICAL achieved operating revenue of 703 million yuan in 2025, down 18.42% year-over-year, with a net loss attributable to the parent company of 119 million yuan, expanding losses by 216.85% year-over-year. Due to a loan dispute, the subsidiary Zhiyu Medical's 51% stake in Delun Medical and some real estate have been frozen by the court for two years, corresponding to a capital contribution of 26.52 million yuan. The company is currently in a state of no actual controller. The board stated that the matters leading to the qualified opinion do not affect normal operations.

"Yangtze River Delta Dental Valley 15th Five-Year Plan" to Be Released Soon; Huishan Oral Ecosystem Conference Signs New Projects

At 14:30 on May 8, the Huishan Digital Oral Ecosystem Conference was held in Hall 105A of the Wuxi International Conference Center. The "Yangtze River Delta Dental Valley 15th Five-Year Development Plan" was released, and five companies including Shuiqing Medical, Sunbiot Dental Group, GF MEDICAL GROUP, Aomendi, and Qianpeng Intelligent were signed. Products launched included Sunbiot Dental's herbal oral care, GF MEDICAL GROUP's 3D-printed jaw guide plates, Aosimei custom correction systems, Aomendi self-locking orthodontic systems, and Haideman steam sterilizers. After the meeting, a new oral material R&D laboratory was inaugurated, and membership was granted to the International Innovation Alliance for Dental Medicines and Medical Devices.

"Huishan · Yangtze River Delta Dental Valley" Showcases Over 100 Products at 2026 Taihu Bay Biomedicine Industry Trade Fair

From May 8 to 10, Huishan · Yangtze River Delta Dental Valley exhibited at booth C02 of the 2026 Taihu Bay Biomedicine Industry Trade Fair, with a 225-square-meter exhibition area showcasing over 100 products in orthodontics, implants, prosthetics, and oral and maxillofacial fields. More than 10 companies, including Angelalign Technology Inc. and Sunbiot Dental Group, participated. This industrial cluster has gathered over 30 companies with an annual output value exceeding 3 billion yuan. The IDTI innovative oral medical device manufacturing base, with a total investment of 1 billion yuan, has been topped out. It is expected that the cluster's annual output value will reach 10 billion yuan after production begins.

Drill-Free Caries Treatment Developer vVARDIS Receives Strategic Investment, Joins Global Unicorn Ranks

On April 15, 2026, Swiss dental medical technology company vVARDIS announced a strategic minority equity investment from Apollo-managed funds. The transaction valued the company at over $1 billion, officially making it a global unicorn. vVARDIS's core strength lies in its patented biomimetic P11-4 peptide technology, offering dental professionals a minimally invasive restorative alternative to traditional drilling. Since launching Curodont™ Repair Fluoride Plus in the U.S. market in 2024, the product has been used to treat approximately 3 million teeth, covering nearly 20% of general dental clinics nationwide. Apollo partner Jeremy Honeth stated that the investment aims to support vVARDIS's continued expansion in the U.S. and European markets.

Dental Manufacturing Company Great Lakes Launches World's First FDA-Cleared 3D-Printed Nylon Oral Appliance

On April 27, 2026, Great Lakes Dental Technologies announced an exclusive laboratory partnership with TAP Sleep Care to launch the Nylon flexTAP®, the world's first FDA-cleared, single-point midline 3D-printed nylon oral appliance. It is primarily used to treat snoring and mild-to-moderate obstructive sleep apnea (OSA). The product uses medical-grade nylon material, featuring ultra-lightweight, ultra-thin, and precise fit characteristics, and is metal-free. It comes standard with a Mouth Shield designed to promote nasal breathing. The Nylon flexTAP® has received full Medicare reimbursement in the U.S. under HCPCS code E0486 and is covered by many commercial insurance plans. As of press time, the company has not disclosed the suggested retail price or approval plans for the Chinese market.